Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 47Breast Neoplasms 9Salivary Gland Neoplasms 2Prostate Adenocarcinoma 2Neoplasm Metastasis 2Breast Neoplasms, Male 2Stage I Prostate Adenocarcinoma AJCC v7 1Sexual Dysfunctions, Psychological 1Salivary Gland Neoplasm Duct 1Primary Dysautonomias 1Patient Compliance 1PSA Level Greater Than Two 1Newly Diagnosed Oligometastatic Prostate Cancer 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia 1Kidney Diseases 1Hypertension 1Hormone Sensitive Prostate Cancer 1Hereditary Sensory and Autonomic Neuropathies 1HER2-positive Breast Cancer 1Granulosa cell tumor of the ovary 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

nirogacestat 1luprolide acetate gel depot 1exemestane 1darolutamide 1X-Rays 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Leuprolide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Granulosa cell tumor of the ovary × Leuprolide × 1 year × Clear all
NCT06169124 2026-05-13

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
37 enrolled

Granulosa cell tumor of the ovary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡